



1FH

## FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP

600 CONGRESS AVENUE, SUITE 2400

AUSTIN, TEXAS 78701-3271

WWW.FULBRIGHT.COM

STEVEN L. HIGHLANDER  
PARTNER  
SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3184  
TELEPHONE: (512) 474-5201  
FACSIMILE: (512) 536-4598

June 18, 2004

### CERTIFICATE OF MAILING 37 C.F.R 1.8

I certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date below:

June 18, 2004

Date

Steven L. Highlander

**MS AMENDMENT**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

RE: *U.S. Patent Application No. 10/824,771 entitled "ASSAY FOR PHOSPHODIESTERASE FUNCTION" – Jackie D. Corbin and Sharron H. Francis*  
*Our reference: VBLT:034US*

Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references C1-C10.

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/VBLT:034US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Steven L. Highlander  
Reg. No. 37,642

SLH/kmv  
Encl.: as noted

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:  
Jackie D. Corbin  
Sharron H. Francis

Serial No.: 10/824,771

Filed: April 15, 2004

For: ASSAY FOR PHOSPHODIESTERASE  
FUNCTION

Group Art Unit: Unknown

Examiner: Unknown

Atty. Dkt. No.: VBLT:034US

CERTIFICATE OF MAILING  
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

June 18, 2004

Date

Steven L. Highlander

INFORMATION DISCLOSURE STATEMENT

**MS AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R. §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be

an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/VBLT:034US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,

  
Steven L. Highlander  
Reg. No. 37,642  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: June 18, 2004

Form PTO-1449 (modified)

JUN 21 2004

U.S. Patent and Trademark Office  
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.

VBLT:034US

Serial No.

10/824,771

Applicant

Jackie D. Corbin

Sharron H. Francis

Filing Date:

April 15, 2004

Group:

Unknown

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

**U.S. Patent Documents**

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

**Foreign Patent Documents**

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

**Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
	C1	Ballard <i>et al.</i> , "Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotid phosphodiesterase isozymes," <i>J. Urol.</i> , 159:2164-2171, 1998.
	C2	Corbin <i>et al.</i> , "Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities," <i>Eur. J. Biochem.</i> , 267:2760-2767, 2000.
	C3	Corbin <i>et al.</i> , "[3H]sildenafil binding to phosphodiesterase-5 is specific, kinetically heterogeneous, and stimulated by cGMP," <i>Mol. Pharmacol.</i> , 63(6):1364-1372, 2003.
	C4	Corbin and Francis, "Cyclic GMP phosphodiesterase-5: target of sildenafil," <i>J. Biol. Chem.</i> , 274(20):13729-13732, 1999.
	C5	Francis <i>et al.</i> , "Phosphorylation of isolated human phosphodiesterase-5 regulatory domain induces an apparent conformational change and increases cGMP binding affinity," <i>J. Biol. Chem.</i> , 277(49):47581-47587, 2002.
	C6	Francis <i>et al.</i> , "Single step isolation of sildenafil from commercially available Viagra tablets," <i>Int. J. Impot. Res.</i> , 15(5):369-372, 2003.
	C7	Gopal <i>et al.</i> , "Allosteric sites of phosphodiesterase-5 (PDE5): a potential role in negative feedback regulation of cGMP signaling in corpus cavernosum," <i>Eur. J. Biochem.</i> , 268:3304-3312, 2001.

25416784.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. VBLT:034US	Serial No. 10/824,771
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Jackie D. Corbin Sharron H. Francis	
		Filing Date: April 15, 2004	Group: Unknown
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### **Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
	C8	Okada and Asakawa, "Allosteric activation of cGMP-specific, cGMP-binding phosphodiesterase (PDE5) by cGMP," <i>Biochemistry</i> , 41:9672-9679, 2002.
	C9	Saenz de Tajada <i>et al.</i> , "The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil," <i>Int. J. Impot. Res.</i> , 13(5):282-290, 2001.
	C10	Turko <i>et al.</i> , "Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (type 5) by sildenafil and related compounds," <i>Mol. Pharmacol.</i> , 56:124-130, 1999.

25416784.1

**EXAMINER:****DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.